• Clinical Insights: September 15, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Aliqopa™ (copanlisib) – September 14, 2017 – The U.S. Food and Drug Administration granted accelerated approval to Aliqopa™ (copanlisib) for the treatment of adults with relapsed… Read more »

  • Clinical Insights: August 25, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Gocovri™ (amantadine) – August 24, 2017 – Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri™ (amantadine) extended release capsules… Read more »

  • Clinical Insights: August 18, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or… Read more »

  • Clinical Insights: August 11, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New… Read more »

  • Clinical Insights: August 4, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vyxeos™ (cytarabine and daunorubicin) – August 3, 2017 – The U.S. Food and Drug Administration approved Vyxeos™ for the treatment of adults with two types of acute… Read more »

  • Clinical Insights: July 28, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) – July 18, 2017 – The U.S. Food and Drug Administration approved Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without… Read more »

  • Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: July 7, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Endari™ (L-glutamine oral powder) – July 7, 2017 – The U.S. Food and Drug Administration approved Endari (L-glutamine oral powder) for patients age five years and older… Read more »

  • Clinical Insights: June 30, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New… Read more »

  • Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »